Bone marrow transplantation for severe aplastic anaemia: cost/benefit of increased immunosuppression.
Gordon-Smith
E C
EC
Division of Haematology, St. George's Hospital Medical School, London, UK.
D000741:Anemia, Aplastic / Q000191:economics / Q000601:surgery* / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000191:economics / Q000379:methods; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D003520:Cyclophosphamide / Q000627:therapeutic use; D003524:Cyclosporins / Q000627:therapeutic use; D006085:Graft Survival / Q000528:radiation effects; D006086:Graft vs Host Disease; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000191:economics* / Q000379:methods; D015182:Lymphatic Irradiation; D014916:Whole-Body Irradiation / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D003115:Colony-Stimulating Factors; D003524:Cyclosporins; D007155:Immunologic Factors; D003520:Cyclophosphamide